Genetic assay is predictive of prognosis for kidney cancer

the ONA take:

Researchers in Singapore have developed a test that has the potential to improve treatment of patients with clear cell renal cell carcinoma (ccRCC). ccRCC is the most common type of kidney cancer.

Treatment options include surgery to remove the tumor and tyrosine kinase inhibitor (TKI) therapy. Prognosis for patients, however, is difficult to predict because outcomes vary. This new test identifies genetic markers of different ccRCC subtypes.

In developing this test, the researchers identified eight genes whose expression levels differed between two subtypes of the disease.

Furthermore, the expression profiles of the eight genes proved to reliably predict good or poor prognosis in patients with ccRCC who received TKI therapy as well as underwent surgery.

The researchers report that the assay could be used as a tool to improve surveillance strategies for patients with ccRCC, but clinical trials are needed to determine the assay’s value in relation to various therapies.

Genetic assay is predictive of prognosis for patients with kidney cancer
A test that has the potential to improve treatment of patients with clear cell renal cell carcinoma.
Singaporean researchers have developed a genetic test that can reliably identify different subtypes of a specific kind of kidney cancer. Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer (see image). The prognosis for patients with ccRCC who undergo surgery to remove a tumor is difficult to predict, however, since outcomes vary.
READ FULL ARTICLE From Medical Express
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs